241 related articles for article (PubMed ID: 28410233)
21. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
22. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
23. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
[TBL] [Abstract][Full Text] [Related]
24. [MED12 gene mutations in women with uterine myoma].
Osinovskaya NS; Ivashchenko TE; Dolinskii AK; Sultanov IY; Ghimbovchi S; Hoffman E; Bezhenar VF; Baranov VS
Genetika; 2013 Dec; 49(12):1426-31. PubMed ID: 25438604
[TBL] [Abstract][Full Text] [Related]
25. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
26. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
27. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
28. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids.
Halder SK; Laknaur A; Miller J; Layman LC; Diamond M; Al-Hendy A
Mol Genet Genomics; 2015 Apr; 290(2):505-11. PubMed ID: 25325994
[TBL] [Abstract][Full Text] [Related]
29. Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.
He C; Nelson W; Li H; Xu YD; Dai XJ; Wang YX; Ding YB; Li YP; Li T
Reprod Sci; 2022 Feb; 29(2):357-365. PubMed ID: 33569750
[TBL] [Abstract][Full Text] [Related]
30. Differential Expression of MED12-Associated Coding RNA Transcripts in Uterine Leiomyomas.
Chuang TD; Gao J; Quintanilla D; McSwiggin H; Boos D; Yan W; Khorram O
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835153
[TBL] [Abstract][Full Text] [Related]
31. Selective genetic analysis of myoma pseudocapsule and potential biological impact on uterine fibroid medical therapy.
Di Tommaso S; Massari S; Malvasi A; Vergara D; Maffia M; Greco M; Tinelli A
Expert Opin Ther Targets; 2015 Jan; 19(1):7-12. PubMed ID: 25363374
[TBL] [Abstract][Full Text] [Related]
32. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
33. High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients.
Wang H; Ye J; Qian H; Zhou R; Jiang J; Ye L
Genet Test Mol Biomarkers; 2015 Mar; 19(3):162-6. PubMed ID: 25615570
[TBL] [Abstract][Full Text] [Related]
34. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
[TBL] [Abstract][Full Text] [Related]
35. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
36. MED12 is frequently mutated in ovarian and other adnexal leiomyomas.
Li Z; Maeda D; Kudo-Asabe Y; Tamura D; Nanjo H; Hayashi A; Ikemura M; Fukayama M; Goto A
Hum Pathol; 2018 Nov; 81():89-95. PubMed ID: 29944972
[TBL] [Abstract][Full Text] [Related]
37. Extracellular matrix (ECM) activates β-catenin signaling in uterine fibroids.
Ko YA; Jamaluddin MFB; Adebayo M; Bajwa P; Scott RJ; Dharmarajan AM; Nahar P; Tanwar PS
Reproduction; 2018 Jan; 155(1):61-71. PubMed ID: 29066531
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma.
Wu J; Zou Y; Luo Y; Guo JB; Liu FY; Zhou JY; Zhang ZY; Wan L; Huang OP
Oncol Lett; 2017 Jul; 14(1):47-54. PubMed ID: 28693134
[TBL] [Abstract][Full Text] [Related]
39. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
40. Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.
Mäkinen N; Heinonen HR; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Br J Cancer; 2014 Apr; 110(9):2246-9. PubMed ID: 24642626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]